论文信息 - Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)

Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)

Limited COVID-19 vaccines in many countries have delayed mass-immunization. Although individuals fully vaccinated with Vaxzevria (AstraZeneca) have higher antibody levels than those with CoronaVac (Sinovac), heterologous prime-boost with CoronaVac-Vaxzevria yielded comparable antibody levels to two-dose Vaxzevria. Combination use of different available vaccines may be warranted in Thailand, which faces limited vaccine choice and supply.

[1] A. Koirala,et al. Vaccines for COVID-19: Where do we stand in 2021? , 2021, Paediatric Respiratory Reviews.

[2] E. Undurraga,et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile , 2021, The New England journal of medicine.

[3] D. Lewis. Mix-and-match COVID vaccines: the case is growing, but questions remain , 2021, Nature.

[4] S. Schneitler,et al. Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens , 2021, medRxiv.

[5] A. Borobia,et al. Reactogenicity and Immunogenicity of BNT162b2 in Subjects Having Received a First Dose of ChAdOx1s: Initial Results of a Randomised, Adaptive, Phase 2 Trial (CombiVacS) , 2021, SSRN Electronic Journal.

[6] N. Suttorp,et al. Reactogenicity of homologous and heterologous prime-boost immunization with BNT162b2 and ChAdOx1-nCoV19: a prospective cohort study , 2021, medRxiv.

[7] A. Thitithanyanont,et al. SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020 , 2020, PloS one.